Media ReleasesNoxopharm

View All Noxopharm News


Noxopharm Announces Positive Clinical Outcomes for NOX66 Reported at ESMO Conference

- Patients with late-stage, metastatic cancers

- NOX66 in combination with carboplatin

- No toxicity associated with NOX66

- Stabilisation of disease process

Sydney, 12 September 2017: Noxopharm (NOX:ASX) presented clinical data from its first-in-human clinical study of NOX66 to the European Society of Medical Oncology Annual Conference in Madrid (Spain) on 11th September 2017.


For further information please download PDF attached:
Download this document